GlassScriptPhysician profile
Gordon W Hendrickson
NPI 1538877071
$5,881.24
in general payments reported to CMS, 2019-2025
50 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.87 · 2023: $2,091 · 2024: $1,963 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,793.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $721.88 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $555.13 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $385.90 | 2023-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $373.47 | 2022-2025 | |
| Lilly USA, LLC | $362.64 | 2022-2025 | Emgality, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $320.57 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $303.28 | 2023-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $277.89 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $274.22 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.94 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $162.19 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $153.61 | 2023-2024 | Eliquis, Camzyos |
| Mylan Specialty L.P. | $141.87 | 2023-2024 | Yupelri |
| Lundbeck LLC | $113.99 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $111.81 | 2023-2025 | Cologuard Collection Kit |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $94.64 | 2024-2025 | Auvelity |
| Corcept Therapeutics | $92.90 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $80.77 | 2023-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $62.18 | 2023-2025 | Zoryve, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.64 | 2023-2024 | Jardiance, Ofev, Spiriva Respimat |
| Nevro Corp. | $59.72 | 2023-2024 | Senza |
| Janssen Pharmaceuticals, INC | $58.35 | 2023 | Xarelto, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.17 | 2024-2025 | Caplyta |
| Actelion Pharmaceuticals US, INC. | $52.42 | 2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $52.31 | 2024 | Watchman Flx, Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $47.39 | 2025 | Rexulti |
| Electromed, INC. | $46.49 | 2023-2025 | Smartvest |
| Grifols USA, LLC | $38.22 | 2024 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $37.60 | 2023-2025 | Austedo Xr, Austedo Xr |
| Astellas Pharma US INC | $37.33 | 2025 | Veozah |
| Lexicon Pharmaceuticals, INC. | $36.09 | 2023 | Inpefa |
| Paratek Pharmaceuticals, INC. | $33.09 | 2025 | Nuzyra |
| Azurity Pharmaceuticals, INC. | $32.37 | 2023 | Edarbi |
| Regeneron Healthcare Solutions, INC. | $32.03 | 2023 | Dupixent |
| Edwards Lifesciences Corporation | $31.56 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $30.04 | 2024-2025 | Verquvo, Gardasil 9, Capvaxive |
| Shield Therapeutics INC | $26.66 | 2024 | |
| Echosens North America, INC. | $24.43 | 2024 | Fibroscan |
| Corium, LLC | $23.47 | 2023 | Azstarys |
| Heartflow, INC. | $22.76 | 2025 | |
| Amneal Pharmaceuticals LLC | $22.53 | 2024 | Ongentys 50mg Capsules 30 |
| Pharmacosmos Therapeutics INC. | $21.93 | 2022 | |
| Seqirus USA INC | $21.12 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Phathom Pharmaceuticals, INC. | $20.88 | 2024 | Voquezna |
| Dexcom, INC. | $20.50 | 2023 | Dexcom G6 Transmitter |
| Bridgebio Pharma, INC. | $17.68 | 2025 | Attruby |
| Baxter Healthcare | $17.37 | 2025 | Hillrom - Synclara Cough System |
| Idorsia Pharmaceuticals US INC | $16.63 | 2024 | Quviviq |
| Organogenesis INC. | $14.82 | 2024 | Novachor |
| Inspire Medical Systems, INC. | $14.76 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Hendrickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.